Bank of New York Mellon’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-77,547
| Closed | -$773K | – | 4217 |
|
|
2025
Q2 | $773K | Buy |
77,547
+12,741
| +20% | +$103K | ﹤0.01% | 3264 |
|
|
2025
Q1 | $387K | Sell |
64,806
-2,441
| -4% | -$17.9K | ﹤0.01% | 3577 |
|
|
2024
Q4 | $516K | Sell |
67,247
-35,918
| -35% | -$309K | ﹤0.01% | 3505 |
|
|
2024
Q3 | $1.05M | Sell |
103,165
-18,085
| -15% | -$276K | ﹤0.01% | 3114 |
|
|
2024
Q2 | $1.8M | Buy |
121,250
+5,409
| +5% | +$77.5K | ﹤0.01% | 2852 |
|
|
2024
Q1 | $1.58M | Sell |
115,841
-8,310
| -7% | -$90.5K | ﹤0.01% | 2897 |
|
|
2023
Q4 | $1.36M | Sell |
124,151
-154,808
| -55% | -$1.53M | ﹤0.01% | 3025 |
|
|
2023
Q3 | $3.05M | Buy |
278,959
+17,090
| +7% | +$219K | ﹤0.01% | 2567 |
|
|
2023
Q2 | $3.47M | Sell |
261,869
-86
| -0% | -$1.23K | ﹤0.01% | 2526 |
|
|
2023
Q1 | $3.57M | Sell |
261,955
-12,418
| -5% | -$222K | ﹤0.01% | 2484 |
|
|
2022
Q4 | $5.36M | Buy |
274,373
+60,082
| +28% | +$1.17M | ﹤0.01% | 2308 |
|
|
2022
Q3 | $4.08M | Buy |
214,291
+33,780
| +19% | +$778K | ﹤0.01% | 2401 |
|
|
2022
Q2 | $3.72M | Sell |
180,511
-6,289
| -3% | -$149K | ﹤0.01% | 2480 |
|
|
2022
Q1 | $6.01M | Buy |
186,800
+84,186
| +82% | +$3.06M | ﹤0.01% | 2322 |
|
|
2021
Q4 | $4.78M | Buy |
102,614
+31,154
| +44% | +$1.04M | ﹤0.01% | 2486 |
|
|
2021
Q3 | $1.93M | Buy |
71,460
+13,330
| +23% | +$348K | ﹤0.01% | 2995 |
|
|
2021
Q2 | $1.49M | Buy |
58,130
+3,019
| +5% | +$71.9K | ﹤0.01% | 3182 |
|
|
2021
Q1 | $1.88M | Buy |
55,111
+13,851
| +34% | +$501K | ﹤0.01% | 2956 |
|
|
2020
Q4 | $1.4M | Buy |
41,260
+12,191
| +42% | +$323K | ﹤0.01% | 3050 |
|
|
2020
Q3 | $718K | Buy |
+29,069
| New | +$782K | ﹤0.01% | 3309 |
|
Other funds holding ITOS
Bank of New York Mellon's ITOS Position: Q3 2025 in Review
Bank of New York Mellon sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 77,547 shares — an estimated $773K sold.
Bank of New York Mellon first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $6.01M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Bank of New York Mellon reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Bank of New York Mellon sold 77,547 iTeos Therapeutics shares in Q3 2025, an estimated $773K.
- Bank of New York Mellon first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Bank of New York Mellon's iTeos Therapeutics position peaked at $6.01M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Bank of New York Mellon's 13F filing for Q3 2025, filed 3 Nov 2025.